Rosetta Signs Marketing Deal for Mesothelioma Test with Tort Claims Administration Firm | GenomeWeb

Rosetta Genomics said this week that it has signed an exclusive marketing deal under which tort claims administration firm PACE Claims Services will provide information about Rosetta's mesothelioma diagnostic test to defendants and insurers in mesothelioma legal cases.

The single largest risk factor for developing mesothelioma is exposure to asbestos, according to Rosetta. Rosetta's miRview Meso is designed to differentiate lung cancer from mesothelioma.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Nature this week: weighting scheme increases GWAS power, and more.

Marc Tessier-Lavigne is to be the next president of Stanford University.

Walgreens has given Theranos 30 days to fix its lab issues, the Wall Street Journal reports.

Journals and research funding agencies pledge to enable the sharing of Zika virus research.